Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 25;18(1):418.
doi: 10.1186/s12884-018-2058-9.

Using a composite adherence tool to assess ART response and risk factors of poor adherence in pregnant and breastfeeding HIV-positive Cameroonian women at 6 and 12 months after initiating option B

Pascal N Atanga  1   2   3 , Harrison T Ndetan  4   5 , Peter N Fon  6 , Henry D Meriki  7   8 , Tih P Muffih  9 , Eric A Achidi  10 , Michael Hoelscher  11   12   13 , Arne Kroidl  12   13
Affiliations

Using a composite adherence tool to assess ART response and risk factors of poor adherence in pregnant and breastfeeding HIV-positive Cameroonian women at 6 and 12 months after initiating option B

Pascal N Atanga et al. BMC Pregnancy Childbirth. .

Abstract

Background: Antiretroviral therapy (ART) adherence in preventing HIV mother-to-child transmission in association with virological suppression and risk factors of low adherence in the Cameroon's Option B+ programme are poorly understood. We used a composite adherence score (CAS) to determine adherence and risk factors of poor adherence in association with virological treatment response in HIV-positive pregnant and breastfeeding women who remained in care at 6 and 12 months after initiating ART.

Methods: We prospectively enrolled 268 women after ART initiation between October 2013 and December 2015 from five facilities within the Kumba health district. Adherence at 6 and 12 months were measured using a CAS comprising of a 6-month medication refill record review, a four-item self-reported questionnaires and a 30-day visual analogue scale. Adherence was defined as the sum scores of the three measures and classified as high, moderate and low. Measured adherence levels were compared to virological suppression rates at month 12 and risk factors of poor adherence were determined.

Results: At 6 and 12 months, 217 (81.0%) and 185 (69.0%) women were available for adherence evaluation. Respectively. Of those, 128 (59.0%) and 68 (31.4%) had high or moderate adherence as per the CAS tool at month 6, and 116 (62.7%) and 48 (24.9%) at month 12, respectively. Viral loads were assessed in 165 women at months 12, and 92.7% had viral suppression (< 1000 copies/mL). Viral suppression was seen in 100% of women with high, 89.5% with moderate, and 52.9% with low adherence using the CAS tool. Virological treatment failure was significantly associated with low adherence [OR 7.6, (95%CI, 1.8-30.8)]. Risk factors for low adherence were younger age [aOR 3.8, (95%CI, 1.4-10.6)], primary as compared to higher levels of education [aOR 2.7, (95%CI, 1.4-5.2)] and employment in the informal sector compared to unemployment [aOR 1.9, (95%CI,1.0-3.6)].

Conclusions: During the first year of Option B+ implementation in Cameroon our novel CAS adherence tool was feasible, and useful to discriminate ART adherence levels which correlated with viral suppression. Younger age, less educated and informal sector employed women may need more attention for optimal adherence to reduce the risk of virological failure.

Keywords: Adherence; Cameroon; Option B +; Risk factors; Viral load.

PubMed Disclaimer

Conflict of interest statement

Competing interest

The authors declare no competing interest.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of the University of Buea and the Ethics Committee at the University of Munich (LMU) in Germany. Administrative authorization to access health facilities within the health district was provided by the regional delegation of Public Health of the South West Region, Cameroon. Participation in the study was free and voluntary and only women who provided a written informed consent were enrolled into the study.

Consent for publication

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Visual Analogue Scale (VAS)
See this image and copyright information in PMC

References

    1. Mills EJ, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. Jama. 2006;296(6):679–690. doi: 10.1001/jama.296.6.679. - DOI - PubMed
    1. Bangsberg DR, Preventing HIV. Antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Supplement_3):S272–S278. doi: 10.1086/533415. - DOI - PubMed
    1. Ngarina M, et al. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus study, Dar Es Salaam, Tanzania. BMC Infect Dis. 2015;15:175. doi: 10.1186/s12879-015-0914-z. - DOI - PMC - PubMed
    1. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: summary of key features and recommendations. June. 2013:2013.
    1. WHO, Consolidated guidelines on the use of antiretroviral drugs for treating and preventing hiv infection: Recommendations for a Public Health approach. 2016. - PubMed

Substances